Prior Authorization in Spravato Billing

Pre-authorization for Spravato (esketamine) is the payer approval process required before treatment begins. Insurance companies require proof that Spravato is medically necessary, clinically appropriate, and compliant with plan-specific rules before they agree to cover the medication and administration.

Understanding these requirements and submitting complete documentation often requires experienced Spravato billing services to avoid delays and help patients access treatment promptly. Below is a streamlined overview of what matters most when submitting a prior authorization for Spravato.

Why Is Prior Authorization Required for Spravato?

Spravato is a high-cost, REMS-restricted medication with safety risks, including sedation and dissociation. Because of this, payers require:

• Clinical justification
• Step-therapy verification
• REMS compliance documentation
• Benefit pathway validation (medical vs pharmacy)

What Patient Information Is Required for Spravato Prior Authorization?

Accurate patient demographics are mandatory. Missing or incorrect data often stalls approvals.

Required patient details include:

• Full legal name
• Date of birth
• Gender
• Phone number and email
• Home address

Insurance documentation must include:

• Policyholder name (exact match to insurance card)
• Plan ID and group number
• Front and back copies of insurance and prescription cards
  

A benefits investigation must be completed before submission to determine:

• Pharmacy benefit vs medical benefit coverage
• Out-of-pocket responsibility
• Correct billing pathway

What Clinical Assessments Are Required for Spravato PA?

Most insurers require a baseline depression severity score using an accepted tool.

Commonly accepted assessments include:

• Beck Depression Inventory (BDI)
• Hamilton Depression Rating Scale (HAM-D)
• Montgomery-Åsberg Depression Rating Scale (MADRS)
• Patient Health Questionnaire-9 (PHQ-9)
• Quick Inventory of Depressive Symptomatology (QIDS-C16)

Always verify payer-specific assessment preferences.

Which Diagnosis Codes Are Accepted for Spravato Authorization?

There is no ICD-10-CM code for treatment-resistant depression (TRD), making accurate Spravato billing & coding essential for payer approval. Payers require base major depressive disorder codes.

1. Accepted ICD-10-CM Codes for New Spravato Patients

• F32.0: MDD, single episode, mild
• F32.1: MDD, single episode, moderate
• F32.2: MDD, single episode, severe without psychotic features
• F32.9: MDD, single episode, unspecified
• F33.0: MDD, recurrent, mild
• F33.1: MDD, recurrent, moderate
• F33.2: MDD, recurrent, severe without psychotic features
• R45.851: Suicidal ideations

2. ICD-10-CM Codes for Patients Continuing Spravato

• F32.4: MDD, single episode, partial remission
• F32.5: MDD, single episode, full remission
• F33.41: MDD, recurrent, partial remission
• F33.42: MDD, recurrent, full remission

Some payers require documentation confirming bipolar disorder has been ruled out.

What Medication History Is Required for Spravato Approval?

This is the most common denial point for Spravato claims. Payers typically require failure of at least two oral antidepressants, though some require more. For each medication trial, document:

• Medication name
• Dosage
• Duration of therapy
• Fill dates (if available)
• Reason for discontinuation
• Evidence of inadequate response or adverse effects

Clearly define what constitutes treatment failure.

Who Can Prescribe Spravato Under Insurance Rules?

Prescriber requirements vary by payer.

Possible requirements include:

• A psychiatrist prescribing directly
• Physician prescribing with psychiatric consultation

Clearly document:

• Prescriber credentials
• Psychiatric consultation notes are provided when required

What Drug and Dosage Information Must Be Included?

Spravato dosage and treatment plan must be clearly specified.

Available dose kits:

• 56 mg dose kit (2 × 28 mg devices)
• 84 mg dose kit (3 × 28 mg devices)

Include:

• Requested dose
• Number of sessions or units
• Day supply
• Indication (TRD or acute suicidal ideation)
• Combination with oral antidepressant when applicable

What Facility Requirements Apply to Spravato Billing?

Spravato can only be administered at REMS-certified facilities.

PA documentation must confirm:

• Facility enrollment in Spravato REMS
• Patient enrollment in Spravato REMS
• Use of REMS-certified pharmacies only

Facility details required:

• Legal name and address
• Phone, fax, and email
• Tax ID (TIN)
• National Provider Identifier (NPI)
• Active licenses and certifications

Common Spravato Prior Authorization Denial Triggers and How to Prevent Them

Understanding common denial triggers helps streamline the prior authorization process and reduces delays in therapy. Addressing these issues proactively can improve approval rates and patient access.

• Missing information: Incomplete PA forms are the most common cause of denials. Ensure every required field is filled out, review payer policy requirements before submission, and include documentation showing nonresponse to at least two oral antidepressants.
• Wrong benefit submission: Submitting under the incorrect benefit can lead to avoidable denials. Verify whether the patient’s coverage is through the pharmacy or medical benefit. If the patient has medical benefit coverage and Spravato is obtained via a specialty pharmacy, confirm the pharmacy is REMS certified and able to process medical benefit claims.
• Step therapy requirements: Failure to meet or document step therapy criteria frequently results in denials. Clearly document all prior therapies, including duration, response, and reasons for discontinuation. If step therapy was not completed, provide a clear clinical justification for bypassing this requirement.
• Specialty pharmacy network issues: Out-of-network pharmacies can delay or block approval. Confirm the specialty pharmacy is in network with the patient’s insurance and, for medical benefit coverage, ensure the pharmacy can process medical authorizations.

Most of these denials are preventable when documentation and submission workflows are aligned with payer-specific requirements, a process often supported by specialized Spravato billing services.

How Does Spravato Reauthorization Work?

Initial Spravato prior authorizations typically last 1 to 3 months, while reauthorizations generally range from 3 to 12 months, depending on payer policy. To secure reauthorization:

• Track clinical progress from day one
• Update assessment scores regularly
• Document symptom improvement or stabilization
• Demonstrate continued medical necessity

Start reauthorization early to avoid treatment gaps.

Final Words

Prior authorization for Spravato is a payer-controlled clinical checkpoint, not an administrative step. Most denials result from misaligned documentation, incorrect benefit pathways, or incomplete medication histories rather than a lack of medical necessity. 

Successful approvals require payer-specific forms, verified REMS enrollment, objective assessment scores, and clearly documented antidepressant failures. Practices that standardize this process secure faster approvals, reduce appeals, and prevent treatment disruptions.